PT Kalbe Farma Tbk (KLBF) Q4 2025 earnings summary

Executive summary

• Net sales grew 8.3% year-over-year to IDR 35.3 tn for FY25, with all major segments except Nutritionals posting growth.

• Net profit increased 13.1% year-over-year, supported by margin improvement and well-managed operating expenses.

• The independent auditor issued an unqualified opinion, confirming fair presentation in accordance with Indonesian Financial Accounting Standards.

• Margin recovery driven by stabilized raw material prices and favorable product mix.

• Strategic partnerships and investments in biologics, radiopharmaceuticals, and local manufacturing underpin future growth.

Financial highlights

• Gross profit margin improved to 39.8% from 39.7% year-over-year.

• Operating profit rose 11.2% to IDR 4.64 tn, with operating margin at 13.1%.

• Net income reached IDR 3.74 tn, up 15.3% year-over-year, with EPS increasing 14.7% to 80.51.

• Cash and cash equivalents at year-end were IDR 4.33 tn, down 8.3% from prior year.

• Dividend payout ratio maintained at 52%.

Outlook and guidance

• Focus on innovation, brand rejuvenation, and expanding preventive health categories.

• Continued investment in local manufacturing and technology transfer to meet regulatory and market demands.

• Management expects sustained growth through product portfolio expansion and operational excellence.

• Management continues to monitor geopolitical risks and macroeconomic volatility, especially related to global supply chains and commodity prices.

• No direct operations in conflict zones, but indirect impacts are being assessed.